Eva Schut

2.0k citations

15 papers · 1.3k · 1 hit paper · h-index 13

Impact in

Oncology top 5%
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
Cancer Research top 10%
- Cancer Genomics and Diagnostics

Papers in

Molecular Biology 10
- Epigenetics and DNA Methylation 3
- Genomics and Chromatin Dynamics 3
- CRISPR and Genetic Engineering 3
- PI3K/AKT/mTOR signaling in cancer 2
- DNA Repair Mechanisms 1
Oncology 9
- PARP inhibition in cancer therapy 3
- Cancer Cells and Metastasis 3
- Cancer-related Molecular Pathways 2

Co-authors: Jos Jonkers (15 shared papers)Eline van der Burg (5 shared papers)Lodewyk F.A. Wessels (8 shared papers)Sjors M. Kas (6 shared papers)Sjoerd Klarenbeek (8 shared papers)Ingrid van der Heijden (2 shared papers)Rinske Drost (2 shared papers)Anne Paulien Drenth (5 shared papers)
Journals: Clinical Cancer Research (2 papers)Cell Reports (1 paper)International Journal of Cancer (1 paper)Nature Genetics (1 paper)Genome Research (1 paper)
Partner nations: Netherlands United Kingdom Germany

In The Last Decade

Eva Schut

15 papers receiving 1.3k citations

Eva Schut's Hit Papers

align trajectories log scale

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis 2019 · 371 citations

Peers

Countries citing papers authored by Eva Schut

Since Specialization

Citations

This map shows the geographic impact of Eva Schut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Schut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Schut more than expected).

Fields of papers citing papers by Eva Schut

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Schut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Schut. The network helps show where Eva Schut may publish in the future.

Co-authors

The 25 scholars most cited alongside Eva Schut, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Schut Line = papers co-authored together Eva Schut links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis Nature ·Max D. Wellenstein, Seth B. Coffelt, Danique E. M. Duits, Martine H. van Miltenburg, Maarten Slagter, Iris de Rink, Linda Henneman, Sjors M. Kas, Stefan Preković, Cheei‐Sing Hau, Kim Vrijland, Anne Paulien Drenth, Renske de Korte‐Grimmerink, Eva Schut, Ingrid van der Heijden, Wilbert Zwart, Lodewyk F.A. Wessels, Ton N. Schumacher, Jos Jonkers, Karin E. de Visser Hit paper breakdown →	2019	371
2	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Clinical Cancer Research ·Bastiaan Evers, Rinske Drost, Eva Schut, Michiel de Bruin, Eline van der Burg, Patrick W.B. Derksen, Henne Holstege, Xiaoling Liu, Ellen van Drunen, H. Berna Beverloo, Graeme C.M. Smith, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Jos Jonkers	2008	273
3	BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance Cancer Cell ·Rinske Drost, Peter Bouwman, Sven Rottenberg, Ute Boon, Eva Schut, Sjoerd Klarenbeek, Christiaan Klijn, Ingrid van der Heijden, Hanneke van der Gulden, Ellen Wientjens, Mark Pieterse, Aurélie Catteau, Peter Green, Ellen Solomon, Joanna R. Morris, Jos Jonkers	2011	211
4	Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland Genes & Development ·Stefano Annunziato, Sjors M. Kas, Micha Nethe, Hatice Yücel, Jessica Del Bravo, Colin E.J. Pritchard, Rahmen Bin Ali, Bas van Gerwen, Bjørn Siteur, Anne Paulien Drenth, Eva Schut, Marieke van de Ven, Mirjam C. Boelens, Sjoerd Klarenbeek, Ivo J. Huijbers, Martine H. van Miltenburg, Jos Jonkers	2016	104
5	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors Clinical Cancer Research ·Bastiaan Evers, Eva Schut, Eline van der Burg, Tanya M. Braumuller, David A. Egan, Henne Holstege, Pauline Edser, David J. Adams, Richard Wade‐Martins, Peter Bouwman, Jos Jonkers	2009	68
6	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation International Journal of Cancer ·Floris H. Groenendijk, Wouter W. Mellema, Eline van der Burg, Eva Schut, Michael Hauptmann, Hugo M. Horlings, Stefan M. Willems, Michel M. van den Heuvel, Jos Jonkers, Egbert F. Smit, René Bernards	2014	63
7	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma Nature Genetics ·Sjors M. Kas, Julian R. de Ruiter, Koen Schipper, Stefano Annunziato, Eva Schut, Sjoerd Klarenbeek, Anne Paulien Drenth, Eline van der Burg, Christiaan Klijn, Jelle J. ten Hoeve, David J. Adams, Marco J. Koudijs, Jelle Wesseling, Micha Nethe, Lodewyk F.A. Wessels, Jos Jonkers	2017	56
8	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma Cell Reports ·Mirjam C. Boelens, Micha Nethe, Sjoerd Klarenbeek, Julian R. de Ruiter, Eva Schut, Nicola Bonzanni, Amber L. Zeeman, Ellen Wientjens, Eline van der Burg, Lodewyk F.A. Wessels, Renée van Amerongen, Jos Jonkers	2016	38
9	Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers BMC Cancer ·Henne Holstege, Erik van Beers, Arno Velds, Xiaoling Liu, Simon A. Joosse, Sjoerd Klarenbeek, Eva Schut, Ron Kerkhoven, Christiaan Klijn, Lodewyk F.A. Wessels, Petra M. Nederlof, Jos Jonkers	2010	34
10	High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors Genome Research ·Marco J. Koudijs, Christiaan Klijn, Louise van der Weyden, Jaap Kool, Jelle ten Hoeve, Daoud Sie, Pramudita R. Prasetyanti, Eva Schut, Sjors M. Kas, Theodore Whipp, Edwin Cuppen, Lodewyk F.A. Wessels, David J. Adams, Jos Jonkers	2011	33
11	Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547 Cancer Research ·Sjors M. Kas, Julian R. de Ruiter, Koen Schipper, Eva Schut, Lorenzo Bombardelli, Ellen Wientjens, Anne Paulien Drenth, Renske de Korte‐Grimmerink, Sunny Mahakena, Christopher Phillips, Paul Smith, Sjoerd Klarenbeek, Koen van de Wetering, Anton Berns, Lodewyk F.A. Wessels, Jos Jonkers	2018	30
12	Somatic structural rearrangements in genetically engineered mouse mammary tumors Genome biology ·Ignacio Varela, Christiaan Klijn, P. J. Stephens, Laura Mudie, Lucy Stebbings, Danushka Galappaththige, Hanneke van der Gulden, Eva Schut, Sjoerd Klarenbeek, Peter J. Campbell, Lodewyk F.A. Wessels, Michael R. Stratton, Jos Jonkers, P. Andrew Futreal, David J. Adams	2010	20
13	A tissue reconstitution model to study cancer cell‐intrinsic and ‐extrinsic factors in mammary tumourigenesis The Journal of Pathology ·Bastiaan Evers, Ewoud N. Speksnijder, Eva Schut, Metamia Ciampricotti, Matthew J. Smalley, Patrick W.B. Derksen, Jos Jonkers, Karin E. de Visser	2009	12
14	Identifying transposon insertions and their effects from RNA-sequencing data Nucleic Acids Research ·Julian R. de Ruiter, Sjors M. Kas, Eva Schut, David J. Adams, Marco J. Koudijs, Lodewyk F.A. Wessels, Jos Jonkers	2017	6
15	Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice Journal of Mammary Gland Biology and Neoplasia ·Lisette M. Cornelissen, Linda Henneman, Anne Paulien Drenth, Eva Schut, Roebi de Bruijn, Sjoerd Klarenbeek, Wilbert Zwart, Jos Jonkers	2019	3

About Eva Schut

Eva Schut is a scholar working on Molecular Biology, Oncology, Genetics, Dermatology and Biotechnology, having authored 15 papers that have together received 1.3k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (3 papers), Epigenetics and DNA Methylation (3 papers), Genomics and Chromatin Dynamics (3 papers), Cancer Cells and Metastasis (3 papers), CRISPR and Genetic Engineering (3 papers), Cancer-related Molecular Pathways (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and DNA Repair Mechanisms (1 paper). The work is most often cited by research in Oncology (679 citations), Cancer Research (215 citations), Molecular Biology (841 citations), Immunology (190 citations) and Genetics (244 citations). Eva Schut has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Jos Jonkers, Eline van der Burg, Lodewyk F.A. Wessels, Sjors M. Kas, Sjoerd Klarenbeek, Ingrid van der Heijden, Rinske Drost, Anne Paulien Drenth, Henne Holstege and Bastiaan Evers. Their work appears in journals such as Clinical Cancer Research, Cell Reports, International Journal of Cancer, Nature Genetics and Genome Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Eva Schut

Impact in

Papers in i

In The Last Decade

Eva Schut

Eva Schut's Hit Papers

Peers

Countries citing papers authored by Eva Schut

Fields of papers citing papers by Eva Schut

All Works

About Eva Schut

Explore authors with similar magnitude of impact

Papers in